全文获取类型
收费全文 | 3849246篇 |
免费 | 324180篇 |
国内免费 | 23226篇 |
专业分类
耳鼻咽喉 | 51566篇 |
儿科学 | 120719篇 |
妇产科学 | 98791篇 |
基础医学 | 596341篇 |
口腔科学 | 104142篇 |
临床医学 | 353567篇 |
内科学 | 674962篇 |
皮肤病学 | 99725篇 |
神经病学 | 317972篇 |
特种医学 | 150401篇 |
外国民族医学 | 306篇 |
外科学 | 586744篇 |
综合类 | 141445篇 |
现状与发展 | 63篇 |
一般理论 | 2363篇 |
预防医学 | 315842篇 |
眼科学 | 91820篇 |
药学 | 274400篇 |
252篇 | |
中国医学 | 21758篇 |
肿瘤学 | 193473篇 |
出版年
2021年 | 59697篇 |
2020年 | 40417篇 |
2019年 | 62114篇 |
2018年 | 76334篇 |
2017年 | 59371篇 |
2016年 | 64458篇 |
2015年 | 80575篇 |
2014年 | 116162篇 |
2013年 | 181808篇 |
2012年 | 115884篇 |
2011年 | 118029篇 |
2010年 | 129731篇 |
2009年 | 131132篇 |
2008年 | 101119篇 |
2007年 | 105138篇 |
2006年 | 113705篇 |
2005年 | 107708篇 |
2004年 | 107030篇 |
2003年 | 96679篇 |
2002年 | 85382篇 |
2001年 | 138052篇 |
2000年 | 131378篇 |
1999年 | 123219篇 |
1998年 | 69296篇 |
1997年 | 65660篇 |
1996年 | 57661篇 |
1995年 | 58462篇 |
1994年 | 52521篇 |
1993年 | 48706篇 |
1992年 | 84857篇 |
1991年 | 81085篇 |
1990年 | 76707篇 |
1989年 | 75053篇 |
1988年 | 68909篇 |
1987年 | 67141篇 |
1986年 | 63412篇 |
1985年 | 62648篇 |
1984年 | 54589篇 |
1983年 | 49180篇 |
1982年 | 43177篇 |
1981年 | 40555篇 |
1980年 | 37997篇 |
1979年 | 44484篇 |
1978年 | 37899篇 |
1977年 | 34477篇 |
1976年 | 31587篇 |
1975年 | 30467篇 |
1974年 | 32242篇 |
1973年 | 30987篇 |
1972年 | 28941篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
991.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献992.
Understanding why persons with human immunodeficiency virus (HIV) have accelerated atherosclerosis and its sequelae, including coronary artery disease (CAD) and myocardial infarction, is necessary to provide appropriate care to a large and aging population with HIV. In this review, we delineate the diverse pathophysiologies underlying HIV-associated CAD and discuss how these are implicated in the clinical manifestations of CAD among persons with HIV. Several factors contribute to HIV-associated CAD, with chronic inflammation and immune activation likely representing the primary drivers. Increased monocyte activation, inflammation, and hyperlipidemia present in chronic HIV infection also mirror the pathophysiology of plaque rupture. Furthermore, mechanisms central to plaque erosion, such as activation of toll-like receptor 2 and formation of neutrophil extracellular traps, are also abundant in HIV. In addition to inflammation and immune activation in general, persons with HIV have a higher prevalence than uninfected persons of traditional cardiovascular risk factors, including dyslipidemia, hypertension, insulin resistance, and tobacco use. Antiretroviral therapies, although clearly necessary for HIV treatment and survival, have had varied effects on CAD, but newer generation regimens have reduced cardiovascular toxicities. From a clinical standpoint, this mix of risk factors is implicated in earlier CAD among persons with HIV than uninfected persons; whether the distribution and underlying plaque content of CAD for persons with HIV differs considerably from uninfected persons has not been definitively studied. Furthermore, the role of cardiovascular risk estimators in HIV remains unclear, as does the role of traditional and emerging therapies; no trials of CAD therapies powered to detect clinical events have been completed among persons with HIV. 相似文献
993.
994.
995.
996.
997.
Canadian Journal of Anesthesia/Journal canadien d'anesthésie - 相似文献
998.
Xi Yu Jennifer Zuk Meaghan V. Perdue Ola Ozernov‐Palchik Talia Raney Sara D. Beach Elizabeth S. Norton Yangming Ou John D. E. Gabrieli Nadine Gaab 《Human brain mapping》2020,41(10):2827-2845
Developmental dyslexia affects 40–60% of children with a familial risk (FHD+) compared to a general prevalence of 5–10%. Despite the increased risk, about half of FHD+ children develop typical reading abilities (FHD+Typical). Yet the underlying neural characteristics of favorable reading outcomes in at‐risk children remain unknown. Utilizing a retrospective, longitudinal approach, this study examined whether putative protective neural mechanisms can be observed in FHD+Typical at the prereading stage. Functional and structural brain characteristics were examined in 47 FHD+ prereaders who subsequently developed typical (n = 35) or impaired (n = 12) reading abilities and 34 controls (FHD?Typical). Searchlight‐based multivariate pattern analyses identified distinct activation patterns during phonological processing between FHD+Typical and FHD?Typical in right inferior frontal gyrus (RIFG) and left temporo‐parietal cortex (LTPC) regions. Follow‐up analyses on group‐specific classification patterns demonstrated LTPC hypoactivation in FHD+Typical compared to FHD?Typical, suggesting this neural characteristic as an FHD+ phenotype. In contrast, RIFG showed hyperactivation in FHD+Typical than FHD?Typical, and its activation pattern was positively correlated with subsequent reading abilities in FHD+ but not controls (FHD?Typical). RIFG hyperactivation in FHD+Typical was further associated with increased interhemispheric functional and structural connectivity. These results suggest that some protective neural mechanisms are already established in FHD+Typical prereaders supporting their typical reading development. 相似文献
999.
1000.
Yu-Tzu Chan Alan C.-Y. Lai Ruey-Jen Lin Ya-Hui Wang Yi-Ting Wang Wen-Wei Chang Hsin-Yi Wu Yu-Ju Lin Wen-Ying Chang Jen-Chine Wu Jyh-Cherng Yu Yu-Ju Chen Alice L. Yu 《International journal of cancer. Journal international du cancer》2020,146(6):1674-1685
G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains unclear. Here we showed greater expression of GPER in BCSCs than non-BCSCs of three patient-derived xenografts of ER−/PR+ breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity in vitro, and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER-mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of PKA and BAD-Ser118 to sustain BCSC characteristics. Transfection with a dominant-negative mutant BAD (Ser118Ala) led to reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs, suggesting that GPER is a potential therapeutic target for eradicating BCSCs. 相似文献